EDC1

About Centrose

Centrose is pioneering a next-generation ADC platform centered on Extracellular Drug Conjugates (EDCs), which function entirely on the cell surface without internalization. This technology leverages the cell 'surfaceome'—specific networks of interacting proteins—to achieve high selectivity and potency while potentially reducing on-target, off-tumor toxicity. The company has a preclinical pipeline targeting metastatic cancers and lymphomas and has demonstrated proof-of-concept in non-human primate studies, positioning it to expand the targetable universe for antibody-conjugate therapies.

Therapeutic Areas